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Synopsis 39 
The implementation of electronic prescribing and medication administration systems (EPMAs) is a 40 
priority for hospitals and a potential component of antimicrobial stewardship. 41 
Objectives 42 
This study aimed to identify software features within EPMAs that could potentially facilitate 43 
antimicrobial stewardship and to survey practising UK infection specialist healthcare professionals in 44 
order to assign priority to these software features. 45 
Methods 46 
A questionnaire was developed using nominal group technique and transmitted via email links 47 
through professional networks. The questionnaire collected demographic data, information on 48 
priority areas and anticipated impact of EPMA. Responses from different respondent groups were 49 
compared using the Mann Whitney U test. 50 
Results 51 
Responses were received from 164 individuals (142 analysable). Respondents were predominantly 52 
specialist infection pharmacists (48%) or medical microbiologists (37%). 59% of pharmacists had 53 
experience of EPMA in their hospitals compared to 35% of microbiologists. Pharmacists assigned 54 
higher priority to: indication prompt (p<0.001), allergy checker (p=0.003) treatment protocols 55 
(p=0.003), drug-indication mismatch alerts (p=0.031) and prolonged course alerts (p=0.041); and 56 
lower priority to a dose checker for adults (p=0.02) and an interaction checker (p<0.05), than 57 
microbiologists. A “soft stop” functionality was rated essential or a high priority by 89% of 58 
respondents. Potential EPMA software features were expected to have the greatest impact on 59 
stewardship, treatment efficacy and patient safety outcomes with lowest impact on Clostridium 60 
difficile infection (CDI), antimicrobial resistance and drug expenditure. 61 
Conclusions 62 
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The survey demonstrates key differences in health professionals’ opinions of different healthcare 63 
benefits of EPMA but a consensus of anticipated positive impact on patient safety and antimicrobial 64 
stewardship.  65 
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INTRODUCTION 66 
Antimicrobial resistance (AMR) is a major threat to public health and a significant resource and cost 67 
burden on the United Kingdom (UK) National Health Service (NHS).1 The Chief Medical Officer’s 2013 68 
report on infections and the rise of AMR called for action to preserve the effectiveness of existing 69 
antimicrobials through antimicrobial stewardship.1 The 2013 UK Five Year Antimicrobial Resistance 70 
Strategy from the Department of Health (DH) also highlights antimicrobial stewardship as one of 71 
seven key areas for action and NHS England has subsequently introduced antimicrobial prescribing 72 
reduction goals for English hospitals through the Commissioning for Quality and Innovation (CQUIN) 73 
programme for 2016/17.2;3   74 
 75 
In 2012, the UK Department of Health commissioned a study of the potential benefits to staff and 76 
patients of greater use of digital and information technology in the NHS and social care.4  The study 77 
report identified four priority actions, one of which was to drive the rollout and use of electronic 78 
prescribing (e-prescribing) in secondary care.  Implementation of e-prescribing systems in hospitals 79 
presents a unique opportunity to improve the quality of antimicrobial prescribing and to facilitate 80 
antimicrobial stewardship.5-10  Evidence for the benefits of antimicrobial stewardship functionality 81 
within e-prescribing systems comes from published research studies demonstrating positive impact 82 
on outcomes including increased guideline adherence11;12 and effective initial therapy13 or reductions 83 
in antimicrobial prescribing,14;15  resistance,16;17 dosing errors,8 length of hospital or ICU stay14;18 and 84 
mortality.12;13;19  However, many of these information systems were created on a small scale in 85 
individual hospitals or groups of institutions and few reports cover the full potential range of 86 
software features that enable antimicrobial stewardship.  Moreover there does not appear to be a 87 
recognised standard to guide the specification and commissioning of an optimal e-prescribing 88 
system that includes the required antimicrobial stewardship functionality appropriate for the 89 
challenges that health systems currently face worldwide.20 90 
 91 
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This report presents results from a cross-sectional survey of UK infection specialist health 92 
professionals. The specific objectives of this study were: to identify, using the nominal group 93 
technique, software features within NHS hospital e-prescribing systems that could potentially 94 
facilitate antimicrobial stewardship; to assign a priority to these software features according to the 95 
opinions of practising infection specialist healthcare professionals; to identify any differences in 96 
priority setting according to professional group, hospital status (teaching or district general) or 97 
previous experience of e-prescribing systems; and to communicate research findings to e-prescribing 98 
software manufacturers and healthcare policy makers. 99 
 100 
MATERIALS AND METHODS 101 
Two focus group meetings of experienced infection health professionals from a local network of 102 
hospitals in the south central region of England were convened in order firstly, to identify software 103 
features within existing e-prescribing and medicines administration (EPMA) systems that facilitate 104 
antimicrobial stewardship and secondly, to identify additional software features with the potential 105 
to facilitate antimicrobial stewardship. The focus groups had representation from six infection 106 
hospital pharmacists (three with experience of EPMA systems), two consultant medical 107 
microbiologists (one with experience of EPMA systems) and one EPMA analyst.  The focus group 108 
meeting output was a list of software features to be included in a questionnaire for wider circulation 109 
among UK infection specialist health professionals.  Following the focus groups, two infection 110 
pharmacists designed a questionnaire using SurveyMonkey® software.  The questionnaire included 111 
42 questions, which were divided into 4 domains. The first domain collected respondent 112 
demographic data including professional group, experience in a specialist role, hospital setting and 113 
EPMA experience.  In the remaining three domains, respondents were asked to assign a priority to 114 
individual software features grouped according to the categories of prescribing alerts/prompts (12 115 
features), active prescription surveillance (11 features) and prescribing trend surveillance (8 116 
features).  At the end of each domain, respondents were asked to express their opinion of the 117 
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anticipated collective impact of the software features from each domain on a number of clinical, 118 
microbiological and process outcomes. For the prescribing trend surveillance domain, respondents 119 
were asked to prioritise a number of technical aspects of the proposed surveillance reports.  Finally, 120 
the questionnaire provided a freetext narrative section inviting respondents to suggest additional 121 
software features with potential to facilitate antimicrobial stewardship, not mentioned earlier in the 122 
survey.  The questionnaire was piloted in the local region, predominately with infection pharmacists 123 
and one medical microbiologist in October 2014.  Feedback from the pilot led to the incorporation of 124 
one additional category (work efficiency) to the list of process outcomes. A copy of the finalised 125 
questionnaire and covering letter to respondents is available as an online Supplement (S1).   126 
 127 
Respondents were advised that participation was voluntary and anonymous, that the questionnaire 128 
would take approximately 10-12 minutes to complete and that the results would be disseminated to 129 
e-prescribing software manufacturers, policy makers and the clinical infection community.  The 130 
research team took the decision not to collect personal details of respondent names and employers 131 
in order to elicit candid responses; although respondent internet protocol (IP) addresses were 132 
collected, identifying responses from the same healthcare organisations.   A hyperlink to the online 133 
questionnaire was distributed via health professional networks including the UK Clinical Pharmacy 134 
Association, the Royal College of Pathologists, the British Society for Antimicrobial Chemotherapy 135 
and Public Health England. The online questionnaire was closed in July 2015, 7 months from launch.  136 
Table 1 presents a glossary of key terms used in the questionnaire that will be referred to 137 
throughout this report. 138 
 139 
Analysis methods 140 
Questionnaire data were summarised with descriptive statistics and analysed using IBM SPSS v.22 141 
with priority ranking of software features by different groups of respondents compared using the 142 
Mann Whitney U test. The respondent groups compared were: specialist pharmacists vs. medical 143 
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microbiologists; respondents from hospitals with EPMA experience vs. those without; and 144 
respondents from teaching hospitals vs. district general hospitals (DGHs). A p-value of <0.05 was 145 
considered statistically significant.  Finally, the freetext narrative comments were analysed by using 146 
a summative approach to qualitative content analysis, grouping responses into common themes 147 
according to frequency of reporting.21  148 
 149 
This research did not require NHS Research Ethics Committee approval for sites in England, Scotland, 150 
Wales or Northern Ireland according to the Health Research Authority online decision tool 151 
(http://www.hra-decisiontools.org.uk/ethics/). 152 
 153 
RESULTS 154 
Respondent accountability 155 
Responses were received from 164 individuals from 79 unique IP addresses. Twenty-two response 156 
sets were removed from the dataset (11 pharmacists, 6 medical microbiologists, one ID physician, 4 157 
nurses and one trainee) due to failure to complete responses to survey questions beyond 158 
demographics. Responses from the remaining 142 individuals from 68 unique IP addresses were 159 
included in the analysis. Eleven of these 142 did not complete all sections of the questionnaire and 160 
missing data were ignored as they comprised less than 10% of responses. 161 
 162 
Respondent demographics 163 
The demographic profile of the 142 respondents included in the analysis is presented in Figure1. 164 
Infection pharmacists comprised almost half of respondents (48%; 68/142) from 39 IP addresses and 165 
the majority had at least 5 years’ experience in a specialist infection role (47/68).   Medical 166 
microbiologists represented over one-third of respondents (37%; 53/142) from 35 IP addresses and 167 
most had at least 5 years’ experience (48/53).  Six infectious diseases (ID) physicians responded to 168 
the survey and a further six respondents were grouped as other healthcare professionals (medical 169 
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virologist, epidemiologist, junior doctor, infection prevention nurse, surveillance nurse and a 170 
consultant in public health). 171 
 172 
Fifty-two per cent of respondents were from district general hospitals (DGHs) (71/136 responses) 173 
and 45% from teaching hospitals (61/136 responses).  Figure 2 illustrates the distribution of 174 
experience of EPMA and electronic prescribing systems amongst the questionnaire respondents.  175 
Approximately half of respondents (49%; 68/139) reported experience of EPMA or electronic 176 
prescribing; 59% of 68 infection pharmacists had experience of EPMA in their hospitals compared to 177 
35% of 52 microbiologists. Forty per cent (56/139) expected implementation of EPMA within 5 years 178 
(25 from teaching hospitals and 29 from district general hospitals) but 11% (15/139) did not expect 179 
EPMA within 5 years (5 from teaching hospitals and 9 from district general hospitals). 180 
 181 
Prescribing Prompt Software Features 182 
Table 2 presents survey response data for priority attributed by respondents to 12 software features 183 
of EPMA systems grouped within the Prescribing Prompt category. The features considered essential 184 
by more than 25% of respondents were: an allergy checking function; a prompt to prescribers to 185 
record the clinical indication for prescribing an antimicrobial; a drug interaction check, a “soft-stop” 186 
feature to indicate a provisional prescription stop date; a prompt to take a blood sample to monitor 187 
drug concentration; and dose checkers for adult and paediatric patients for all antimicrobials.  188 
 189 
Specialist pharmacists assigned higher priority to: indication prompt (p<0.001); allergy checker 190 
(p=0.003); and treatment protocols (p=0.003) (Table 3).  Medical microbiologists assigned higher 191 
priority to a dose checker for adults (p=0.023) and an interaction checker (p<0.05).   Respondents 192 
from hospitals with EPMA experience assigned higher priority to an indication prompt (p=0.049). 193 
Respondents from hospitals without EPMA experience assigned higher priority to: restricted 194 
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antimicrobial block (p=0.011); dose checker for children (p=0.024); and blood level monitoring alert 195 
(p=0.033). When responses from teaching hospitals were compared with responses from DGHs, 196 
there were no statistically significant differences in opinions of priority for any of the prescribing 197 
prompt software features.  The majority of respondents considered that both patient safety (60%; 198 
84/140) and ability to deliver antimicrobial stewardship (64%; 89/140) were extremely likely to be 199 
improved (Figure 3). 200 
 201 
Active Prescription Surveillance Software Features 202 
Table 4 presents survey response data for priority attributed by respondents to 11 software features 203 
of EPMA systems grouped within the Active Prescription Surveillance category. The features 204 
considered essential by more than 25% of respondents were daily reports of: new and ongoing 205 
prescriptions for critical antimicrobials; mismatch between prescribed antimicrobials and their 206 
corresponding indications; long course lengths; and missed doses.   207 
 208 
Specialist pharmacists assigned higher priority to a daily report of mismatch between prescribed 209 
antimicrobial and associated indication (p=0.031) and long IV/oral courses (p=0.041) (Table 3).  210 
Respondents from hospitals with EPMA experience assigned higher priority to: a daily report of 211 
newly-prescribed critical antimicrobials (p=0.015); and a daily report of any newly-prescribed 212 
antimicrobial (p=0.024). When responses from teaching hospitals were compared with responses 213 
from DGHs, there were no statistically significant differences in opinions of priority for any of the 214 
active prescription surveillance software features.  The majority (>50%) of respondents considered 215 
that both patient safety (30%; 71/135) and ability to deliver antimicrobial stewardship (31%; 80/134) 216 
were extremely likely to be improved (Figure 4). Two respondents expressed the view that an 217 
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improvement in outcomes was extremely unlikely: reduction in expenditure on drugs; and a 218 
reduction in risk of Clostridium difficile. 219 
 220 
Prescribing Trend Surveillance Software Features 221 
Prescribing trend surveillance reports as a software feature were generally considered by 222 
respondents to be of lower priority compared with prescribing prompts and active prescription 223 
surveillance, with only two software feature rated as essential by more than 25% of respondents; 224 
reports of trends in point prevalence (proportion of patients prescribed an antimicrobial at a specific 225 
point in time); and reports of trends in missed doses (Table 5).  There were no statistically significant 226 
differences in opinions of priority for prescribing trend surveillance software features between 227 
specialist pharmacists and medical microbiologists, nor between respondents with or without EPMA 228 
experience.  Respondents from DGHs assigned a higher priority to the report of trends in proportion 229 
of stat doses where administration was delayed software feature (p=0.034) (Table 3).  At least two-230 
thirds of respondents considered that the prescribing trend surveillance group of software features 231 
would be likely or extremely likely to have a positive impact on all of the listed clinical, 232 
microbiological and process outcomes (Figure 5). More than 90% of respondents anticipated a 233 
positive impact on their ability to deliver antimicrobial stewardship. 234 
 235 
Respondent opinions of selected technical aspects of prescribing trend surveillance reporting are 236 
summarised in Table 6.  Respondents expressed equal preference for patient days or patient 237 
admissions as an activity denominator. A preference for annual and quarterly reporting intervals was 238 
considered to be of very high importance by at least 40% of respondents.  Surveillance reports for 239 
the whole hospital and by clinical speciality and hospital department were rated of very high 240 
importance by at least 40% of respondents, whereas reports by individual responsible consultant 241 
physician were considered of lesser importance. Finally, surveillance reports of prescribing and 242 
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administration of individual antimicrobials, by antimicrobial drug class and by locally defined drug 243 
groups such as broad-spectrum agents were rated most highly by respondents with reports grouped 244 
by route of administration considered of lesser importance. 245 
 246 
Freetext narrative responses 247 
Thirty-five respondents recorded narrative responses when prompted to submit suggestions for 248 
additional software features not included in the questionnaire and 69 unique statements were 249 
identified and grouped into nine common themes, presented in Table 6. Eighteen respondents 250 
suggested an interface with other electronic systems for previous and current microbiology 251 
investigations and results and for drug and clinical information to guide prescribing. There was an 252 
apparent demand for flexibility in reporting software to allow reports to be customised locally but 253 
also to generate a standard set of reports for reporting to Public Health England in accordance with 254 
antimicrobial stewardship guidance for English Hospitals: Start Smart – Then Focus.22 255 
 256 
DISCUSSION 257 
This is the first survey of UK infection specialist healthcare professionals evaluating opinions of the 258 
potential for electronic prescribing software to facilitate antimicrobial stewardship.  The two largest 259 
health professional groups responsible for antimicrobial stewardship are represented. We estimate 260 
an approximate response rate (n=68) of 24% of NHS hospital specialist infection pharmacists and at 261 
least 9% of practising UK medical microbiologists.23;24 Responses were included from 68 unique IP 262 
addresses representing up to 36% (68/188) of NHS hospital trusts/boards if the questionnaire was 263 
completed from the employing hospital’s IP address.25-28  The responses represented opinions of 264 
experienced healthcare professionals, as the majority (79%; 106/134) had worked in a specialist role 265 
for more than 5 years.  Teaching hospitals are proportionately over-represented compared with 266 
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DGHs but there was a good balance of respondents with experience of EPMA systems and those 267 
without. 268 
 269 
The prescribing prompt software features ranked of highest priority by respondents were allergy 270 
checker, interaction checker and dose checker, which are already incorporated as standard 271 
functionality in a number of existing e-prescribing systems in NHS hospitals.29  The response data 272 
suggest an unmet need for prescribing prompt software features that are particularly relevant to 273 
antimicrobial prescribing such as recording of indication and “soft stop” functionality; that are not 274 
routinely incorporated into existing e-prescribing systems.  The responses suggest relatively little 275 
appetite among UK infection specialists for software features to support restriction of prescribing of 276 
selected antimicrobials, possibly reflecting the inter-speciality conflict inherent in such policies, 277 
resource implications and the lack of longer-term superiority over persuasive interventions.30  278 
Priorities for active prescription surveillance software features were divided between an emphasis 279 
on patient safety (drug-indication mismatch and missed doses) and antimicrobial stewardship 280 
(prescriptions for critical antimicrobials and long course lengths).  Reports of new or ongoing 281 
prescriptions of any antimicrobial were considered lower priority, potentially reflecting the limited 282 
resources available to antimicrobial stewardship teams.31  While respondents were less likely to rank 283 
proposed software features from the prescribing trend surveillance group as essential, all of these 284 
software features were considered at least high priority by over two-thirds of the responding 285 
clinicians, suggesting a perception of value from longer-term surveillance data for monitoring 286 
performance and measuring the impact of prescribing interventions.  Opinions of the expected 287 
impact of the proposed prescribing prompt and active prescription surveillance software features on 288 
patient outcomes, public health outcomes and resource use outcomes were overwhelmingly 289 
positive.  It is particularly striking that more than 90% of respondents considered prescribing prompt 290 
software features and active prescription surveillance features either likely or extremely likely to 291 
improve patient safety, corroborated by an expectation of improved treatment efficacy and reduced 292 
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Clostridium difficile infection.  A positive impact of all three groups of software features on their 293 
ability to deliver stewardship and efficient deployment of stewardship resources was especially 294 
evident from the responses. 295 
 296 
We found that pharmacists were more likely to prioritise a prescribing prompt to record indication, 297 
which may reflect the uncertainty faced by hospital pharmacists when validating new prescriptions 298 
for antimicrobials (for safety and effectiveness) prior to authorising dispensing; and the requirement 299 
to audit antimicrobial prescribing for adherence to local treatment guidelines.22;32 A relative 300 
preference amongst pharmacist respondents for a treatment protocol software feature is consistent 301 
with the finding that pharmacist respondents also ranked daily reports of drug-indication mismatch 302 
a higher priority in comparison to medical microbiologists.  We found that medical microbiologists 303 
were more likely to prioritise prescribing prompts for dose checking and interaction checking in 304 
comparison to pharmacists, perhaps indicating differences in undergraduate teaching and endorsing 305 
the value of a multi-disciplinary approach to infection management. 306 
 307 
Respondents from hospitals with experience of EPMA systems ranked the indication prompt feature 308 
as relatively more important in comparison to those without, suggesting an unmet need amongst 309 
existing software systems.  We observed remarkable consistency between the priorities assigned to 310 
software features by respondents from teaching hospitals and those from DGHs. When technical 311 
aspects of surveillance reports were considered, it is of interest that reports by individual 312 
responsible consultant physician were considered of lesser importance than reports by clinical 313 
speciality or hospital department.  This finding suggests a lack of willingness to employ a “name-and-314 
shame” approach to stewardship and may represent a preference for promoting a sense of 315 
collective responsibility amongst clinician colleagues.  Freetext comments identified strong user 316 
demand for an interface with the microbiology laboratory software system to support selection of 317 
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effective therapy and de-escalation and to facilitate prompt intervention when patients are 318 
prescribed potentially ineffective therapy. 319 
 320 
This cross-sectional survey was designed in accordance with recommended principles of health 321 
professional survey design as far as possible within the available resources.33;34  However, a shorter 322 
questionnaire may have improved the response rate.33  The exclusion of data relating to address or 323 
employer means that we cannot rule out the possibility that multiple responses may have been 324 
submitted by the same individuals and it is likely that multiple respondents from the same Trust had 325 
an effect on our findings.  We were also unable to collect information on non-responders so the 326 
respondent sample is likely to be biased towards more motivated individuals who are engaged with 327 
quality improvement and/or information technology. Approximately half of respondents reported 328 
experience of EPMA or electronic prescribing and this suggests a bias towards hospitals with such 329 
systems when compared with a survey carried out by Public Health England in 2014 which reported 330 
only 17/76 (22%) of respondent hospitals with e-prescribing for at least one inpatient area.35 The 331 
questionnaire did not specifically elicit a description of the existing software features of EPMA 332 
systems currently installed in NHS hospitals but anecdotal evidence from the research team and 333 
from professional networks in the UK suggests that software features to support antimicrobial 334 
stewardship are extremely limited.  Finally, the present questionnaire was primarily distributed by e-335 
mail to members of professional organisations and therefore may not represent the views of non-336 
members. 337 
 338 
The target audience for this survey – consultant medical microbiologists and specialist pharmacists – 339 
was deliberate, to focus on individuals most likely to be responsible for stewardship within an NHS 340 
hospital organisation.  However, other healthcare workers also play an important role in 341 
antimicrobial stewardship at the individual patient level including junior and senior doctors, nurses, 342 
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non-medical prescribers and ward pharmacists.36-41 Inclusion of these professional groups in user-343 
testing at the design stage of EPMA implementation is likely to be critical to the success of the 344 
proposed software features. Future surveys focussing on front-line prescribers and medication 345 
administrators are critical. 346 
 347 
The advent of e-prescribing to NHS hospitals represents a unique new opportunity to engage with 348 
healthcare professionals to promote safe, effective and proportionate antimicrobial prescribing and 349 
to refresh the antimicrobial stewardship message. It must be acknowledged however that with this 350 
opportunity also comes new threats to patient safety from prescribing and administration errors as 351 
well as potential de-skilling of healthcare professionals.42-44   The judicious use of educational 352 
prompts may facilitate a sustained change in prescribing behaviour but this must be balanced 353 
against the recognised risk of “alert fatigue” and competing priorities for e-prescribing system 354 
functionality from other medical and surgical specialities.45  Successful implementation of the 355 
proposed antimicrobial stewardship software features into e-prescribing systems will likely be 356 
contingent upon a variety of sociotechnical considerations including seamless integration into the 357 
prescribing workflow with minimal time penalties for end-users and full compatibility with existing 358 
NHS information technology hardware and software.43;46   359 
 360 
This survey represents the first attempt to canvas opinion of infection specialists in the UK on the 361 
potential for e-prescribing software to support antimicrobial stewardship.  The survey results reveal 362 
considerable demand for additional software features expressed by the healthcare professionals 363 
charged with promoting rational use of antimicrobials and a consensus of anticipated positive 364 
impact on patient safety and efficiency outcomes. The survey demonstrates key differences in health 365 
professionals’ opinions of different healthcare benefits of EPMA and underscores the need for a 366 
multi-disciplinary approach to the development of EPMA system specifications. We trust this 367 
information will prove valuable to software manufacturers currently developing e-prescribing 368 
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systems when prioritising software functionality and systems interface development and potentially 369 
to healthcare commissioners when drafting e-prescribing system specifications. Finally, we 370 
commend this topic to research funders with a view to funding research into the potential benefits 371 
and unintended consequences of e-prescribing system functionality designed to support 372 
antimicrobial stewardship. 373 
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Table 1.  Glossary of key terms used in the survey of opinions of infection specialists on electronic 524 
prescribing and antimicrobial stewardship 525 
Term Explanation 
Prescribing alert / 
prompt 
The prescriber will be alerted via a “pop-up” message – an “alert or 
prompt” – e.g. if attempting to prescribe an antimicrobial which is contra-
indicated because of an allergy or a drug interaction 
Active prescription 
surveillance 
Active prescription surveillance refers to the application of surveillance 
data in real-time for identification of patients currently prescribed 
antimicrobial therapy.  Software features allow prioritisation of patients 
for intervention by the antimicrobial stewardship team (AST). 
 
Active prescription surveillance reports would typically include: patient 
name, date of birth, hospital number, inpatient location in the hospital, 
drug name, drug dose, start date, stop date (if specified), prescriber and 
responsible senior physician. 
Prescribing trend 
surveillance 
Prescribing trend surveillance refers to the review of retrospective data 
relating to antimicrobial prescribing and administration – typically as 
trends over time. Prescribing trend surveillance allows continuous 
monitoring of performance for the purposes of controls assurance and for 
evaluating the impact of stewardship interventions. 
Order Sets This software feature allows the prescriber to select an infection (e.g. 
pneumonia, community-acquired, severe) and the system will 
automatically populate the prescription with the locally pre-defined 
treatment regimen (single drug or combination of drugs) at standard 
doses. 
Critical antimicrobial An antimicrobial may be designated “critical” by a hospital AST according 
to local priorities – for example, broad-spectrum antimicrobials such as 
carbapenems or antimicrobials with a narrow therapeutic range such as 
colistin. A prescriber may be alerted when prescribing a critical 
antimicrobial with an appropriate locally-defined message containing 
details of actions required when prescribing. 
Restricted 
antimicrobial 
An antimicrobial may be designated “restricted” by a hospital AST on 
grounds of financial cost, propensity to predispose to Clostridium difficile 
infection or local decision to reserve for multidrug-resistant infections. 
Prescribing of restricted antimicrobials requires pre-authorisation by a 
medical microbiologist or infectious diseases physician (“restricted 
antimicrobial authorisation”) or prescribing is limited by the prescribing 
software to senior clinicians (“restricted antimicrobial block”). 
Soft Stops This software feature allows the prescriber to nominate a date when the 
antimicrobial prescription should be reviewed with a view to stopping, 
changing treatment or switching route of administration to oral. After the 
review date has passed, the drug will remain visible and available to 
nursing staff to administer but will be prominently highlighted as being 
past the review (soft stop) date 
Blood level monitoring 
order set 
When a relevant drug is prescribed, the EPMA system will automatically 
pair the drug prescription with an order for a blood specimen to be taken 
at an appropriate time post-dose. 
Drug-indication A mismatch occurs when a prescribed antimicrobial is not appropriate or 
23 
 
mismatch unauthorised for the recorded indication/provisional diagnosis. 
Days of Therapy (DOTs) One DOT represents the administration of a single systemic antimicrobial 
on a given day regardless of the number of doses administered or dosage 
strength. For example, administration of ceftriaxone as 4g once-daily or as 
2g twice-daily for one day would both represent 1 DOT. A single patient 
receiving both vancomycin and ceftazidime during the same day would be 
recorded as receiving 2 DOTs (1 of vancomycin and 1 of ceftazidime).47   
Length of Therapy 
(LOT) 
LOT refers to antimicrobial course length and is the number of sequential 
days that a patient receives any systemic antimicrobial drug(s), 
irrespective of the number of different drugs.47  A prescription of 
intravenous piperacillin-tazobactam and vancomycin for 2 days followed 
by oral co-amoxiclav for 5 days corresponds to a LOT of 7 days. 
Point Prevalence Point prevalence is the proportion of hospital patients active on the EPMA 
system that are prescribed any antimicrobial at a specific point in time 
(for example at noon on the first day of each month). 
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Table 2.  Prescribing Prompt software features ranked in order of respondent-assigned priority 534 
Software 
feature 
Number of 
responses 
Essential 
High 
priority 
Medium 
priority 
Low 
priority 
Not a 
priority 
Allergy 
checker 
142 80.3% 14.8% 3.5% 1.4% 0.0% 
Indication 
prompt 
139 56.8% 30.9% 10.8% 1.4% 0.0% 
Interaction 
checker 
143 45.5% 35.7% 14.7% 4.2% 0.0% 
Soft stop 
141 38.3% 51.1% 7.1% 2.8% 0.7% 
Blood level 
prompt 
140 35.0% 46.4% 15.7% 2.9% 0.0% 
Dose checker 
(children) 
142 33.8% 44.4% 19.0% 2.1% 0.7% 
Dose checker 
(adults) 
141 25.5% 48.2% 22.0% 3.5% 0.7% 
Critical 
antimicrobial 
prompt 
141 24.1% 48.2% 21.3% 4.3% 2.1% 
Indication 
order set 
143 21.7% 45.5% 25.2% 4.9% 2.8% 
Blood level 
order set 
140 21.4% 39.3% 29.3% 9.3% 0.7% 
Restricted 
antimicrobial 
require 
authorisation 
142 18.3% 25.4% 30.3% 17.6% 8.5% 
Restricted 
antimicrobial 
block by 
prescriber 
140 15.7% 31.4% 26.4% 16.4% 10.0% 
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Table 3.  Differences in software feature priority assignment between respondent groups found to 537 
be statistically significant 538 
Domain / 
Respondent 
group 
Software feature Respondent group  
(% of responses rated essential) 
Mann-
Whitney U 
test p-value 
Professional 
group 
 Pharmacists Medical 
microbiologists 
 
Prescribing 
prompts 
Allergy checker 90% 69% p=0.003 
(n=68, 52) 
Indication prompt 73% 39% p<0.001 
(n=67, 51) 
Treatment protocols 28% 15% p=0.003 
(n=68, 53) 
Dose checker (adults) 16% 34% p=0.023 
(n=68, 53) 
Interaction checker 34% 51% p=0.047 
(n=68, 53) 
Active 
prescription 
surveillance 
Drug-indication mismatch 35% 25% p=0.031 
(n=65, 49) 
Long IV/oral course 31% 24% p=0.041 
(n=65, 50) 
EPMA 
experience 
 EPMA-
experienced 
Non EPMA-
experienced 
 
Prescribing 
prompts 
Indication prompt 66% 47% p=0.049 
(n=68, 68) 
Restricted antimicrobial block 12% 17% p=0.011 
(n=67, 70) 
Dose checker (children) 26% 39% p=0.024 
(n=68, 70) 
Blood level monitoring alert 24% 44% p=0.033 
(n=67, 70) 
Active 
prescription 
surveillance 
Daily report of newly-prescribed 
critical antimicrobials 
64% 40% p=0.015 
(n=64, 68) 
Daily report of any newly-
prescribed antimicrobial 
23% 16% p=0.024 
(n=64, 68) 
Hospital type  Teaching District 
General 
 
Prescribing 
trend 
surveillance 
Report of trends in proportion of 
stat doses where administration 
was delayed 
28% 18% p=0.034 
(n=55, 65) 
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Figure 3.  Respondent opinions of the likely impact of Prescribing Prompt software features  541 
on clinical, microbiological and process outcomes 542 
 543 
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  545 
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Table 4.  Active Prescription Surveillance software features ranked in order of respondent-546 
assigned priority 547 
Software 
feature 
Number of 
responses 
Essential 
High 
priority 
Medium 
priority 
Low 
priority 
Not a 
priority 
New Rx of 
critical drug 
135 51.9% 41.5% 6.7% 0.0% 0.0% 
Ongoing Rx of 
critical drug 
135 42.2% 42.2% 15.6% 0.0% 0.0% 
Drug-indication 
mismatch 
134 31.3% 47.8% 17.9% 3.0% 0.0% 
Long IV/oral 
course 
135 28.9% 54.8% 14.8% 0.7% 0.7% 
Missed Abx 
doses 
132 26.5% 43.9% 22.7% 6.1% 0.8% 
Long IV course 132 25.0% 59.8% 14.4% 0.8% 0.0% 
High-dose 
aminoglycoside 
133 23.3% 40.6% 25.6% 9.0% 1.5% 
New Rx for 
sepsis of 
unknown origin 
134 20.1% 57.5% 19.4% 1.5% 1.5% 
New Rx of any 
antibiotic 
136 19.1% 27.9% 33.1% 17.6% 2.2% 
Ongoing Rx of 
any antibiotic 
133 13.5% 30.8% 36.1% 15.0% 4.5% 
New Rx for  
diagnosis of 
interest 
135 13.3% 51.9% 30.4% 3.0% 1.5% 
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Figure 4. Respondent opinions of the likely impact of Active Prescription Surveillance software 551 
features on clinical, microbiological and process outcomes 552 
 553 
  554 
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Table 5.  Prescribing Trend Surveillance software features ranked in order of respondent-assigned 555 
priority 556 
Software 
feature 
Number of 
responses 
Essential 
High 
priority 
Medium 
priority 
Low 
priority 
Not a 
priority 
Trends in 
point 
prevalence 
130 29.2% 44.6% 23.1% 2.3% 0.8% 
Trends in 
missed 
doses 
130 26.9% 45.4% 24.6% 2.3% 0.8% 
Trends in 
delayed stat 
doses 
130 23.1% 53.8% 19.2% 3.8% 0.0% 
Trends in 
total days of 
therapy 
(DOTs) 
130 13.1% 39.2% 37.7% 7.7% 2.3% 
Trends in 
average 
length of 
therapy 
(LOT) 
131 13.0% 53.4% 29.0% 3.8% 0.8% 
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Figure 5:  Respondent opinions of the likely impact of Prescribing Trend Surveillance software 560 
features on clinical, microbiological and process outcomes 561 
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Table 6: Respondent opinions of technical aspects of prescribing trend surveillance reporting 564 
software features ranked in order of respondent-assigned priority 565 
 Response 
Count 
Importance attributed by respondents 
Very high High Moderate Some None 
ACTIVITY DENOMINATOR 
EPMA patient 
days (total 
number of 
patients 
multiplied by 
number of 
days) 
130 16.2% 40.0% 31.5% 10.8% 1.5% 
EPMA 
admissions 
(new patients) 
130 13.8% 38.5% 36.2% 10.8% 0.8% 
REPORT TIME INTERVALS 
Annually 130 48.5% 31.5% 13.1% 3.8% 3.1% 
Quarterly 130 40.0% 42.3% 13.8% 2.3% 1.5% 
Monthly 130 24.6% 36.9% 29.2% 6.9% 2.3% 
Weekly 129 7.8% 20.9% 27.9% 28.7% 14.7% 
Daily 130 4.6% 15.4% 22.3% 26.2% 31.5% 
HOSPITAL SUBDIVISIONS 
Whole hospital 129 49.6% 38.8% 6.2% 4.7% 0.8% 
Clinical 
speciality 
128 42.2% 41.4% 11.7% 3.9% 0.8% 
Hospital 
departments 
128 40.6% 36.7% 16.4% 4.7% 1.6% 
Wards 128 32.8% 39.1% 21.1% 5.5% 1.6% 
Responsible 
consultant 
physician 
129 32.6% 37.2% 20.2% 9.3% 0.8% 
DRUG GROUPINGS 
Individual 
drugs 
129 48.8% 36.4% 10.9% 2.3% 1.6% 
Drug class (e.g. 
macrolides) 
128 41.4% 41.4% 13.3% 3.9% 0.0% 
Locally-defined 
drug group 
(e.g. broad-
spectrum, 
narrow-
spectrum) 
130 40.0% 38.5% 16.9% 4.6% 0.0% 
Antibacterials, 
antifungals, 
antivirals, 
antiparasitics 
127 33.9% 37.0% 15.7% 13.4% 0.0% 
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All 
antimicrobials 
130 30.0% 36.9% 19.2% 11.5% 2.3% 
By route of 
administration 
129 24.0% 40.3% 24.8% 8.5% 2.3% 
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Table 7.  Thematic analysis of freetext narrative responses to the question: “Do you have any 569 
other suggestions for potential functionality for electronic prescribing and medicines 570 
administration systems?” 571 
Theme Frequency Details of additional user requirements 
Microbiology laboratory system 
interface 
13  Susceptibility testing – prescription conflict 
(“drug-bug mismatch”) 
 Previous microbiology including healthcare-
associated infections 
Reporting functions 9  Flexibility of reporting – capacity to customise 
reports locally 
 Reporting to national standard (Start Smart – 
Then Focus) 
 Defined daily doses in addition to DOTs 
Clinical information system 
interface 
5  Link to guidelines 
 Drug information: adverse effects, drug 
administration, drug monitoring 
 Disease severity scoring systems 
Restriction systems 5  Authorisation codes 
 Authorisation by named specialist 
 System access restricted to trained prescribers 
 Compulsory recording of indication 
Additional narrative fields 5  Infection specialist advice 
 Justification for off-guideline prescribing 
 Precise nature of drug allergy 
 Reasons for missed doses 
Soft stops / review dates 4  Block administration until review 
 Patient safety of automatic prescription stop 
Dosing support 3  Dosing by age, weight and renal function 
Drug history 3  Primary care and previous hospital admissions 
Stat doses 3  Automatic associated stat dose and 
appropriately spaced maintenance dose 
 Stat dose remains visible if delayed 
Miscellaneous 19  
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